Evidence map›Paper›PMID 35925991›Full record

ArticlePloS one2022

Impact of pre-treatment prognostic nutritional index and the haemoglobin, albumin, lymphocyte and platelet (HALP) score on endometrial cancer survival: A prospective database analysis.

Kelechi Njoku, Chloe E Barr, Neal C Ramchander, Emma J Crosbie

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kelechi NjokuDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, St Mary's Hospital, University of Manchester, Manchester, United Kingdom.ORCID 0000-0001-6528-3476
Chloe E BarrDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, St Mary's Hospital, University of Manchester, Manchester, United Kingdom.
Neal C RamchanderDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, St Mary's Hospital, University of Manchester, Manchester, United Kingdom.
Emma J CrosbieDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, St Mary's Hospital, University of Manchester, Manchester, United Kingdom.
Manchester Academic Health Science Centre · GBUniversity of Manchester · GB

Funding

Cancer Research UK C147/A25254Department of Health IS-BRC-1215-20007Department of Health NIHR300650Wellcome Trust
6 · The paper itself

Abstract

purposeThe Onodera's prognostic nutritional index (PNI) and the haemoglobin, albumin, lymphocyte and platelet (HALP) score are immune-nutritional indices that correlate with survival outcomes in several adult solid malignancies. The aim of this study was to investigate whether PNI and HALP are associated with survival outcomes in endometrial cancer. PATIENTS AND

methodsWomen undergoing management for endometrial cancer were recruited to a single centre prospective cohort study. Pre-treatment PNI and HALP scores were computed for study participants and analysed as continuous variables and by selecting cut-off values based on previous publications. Both parameters were analysed in relation to overall, endometrial cancer-specific and recurrence-free survival using Kaplan-Meier estimation and multivariable Cox proportional regression.

resultsA total of 439 women, with a median age of 67 years (interquartile range (IQR), 58, 74) and BMI of 31kg/m2 (IQR 26, 37) were included in the analysis. Most had low-grade (63.3%), early-stage (84.4% stage I/II) endometrial cancer of endometrioid histological subtype (72.7%). Primary treatment was surgery in 98.2% of cases. Adjusted overall mortality hazard ratios for PNI and HALP as continuous variables were 0.97(95%CI 0.94-1.00, p = 0.136) and 0.99(95%CI 0.98-1.01, p = 0.368), respectively. Women with pre-treatment PNI ≥45 had a 45% decrease in both overall (adjusted HR = 0.55, 95% CI 0.33-0.92, p = 0.022) and cancer-specific mortality risk (adjusted HR = 0.55, 95%CI 0.30-0.99, p = 0.048) compared to those with PNI <45. There was no evidence for an effect of PNI on recurrence free survival. HALP scores were associated with adverse clinico-pathologic factors, but not overall, cancer-specific or recurrence-free survival in the multivariable analysis.

conclusionPNI is an independent prognostic factor in endometrial cancer and has the potential to refine pre-operative risk assessment.

Indexed as

Endometrial NeoplasmsNutrition AssessmentAgedAlbuminsFemaleHemoglobinsHumansLymphocytesMiddle AgedPrognosisProspective StudiesSurvival RateAlbuminsHemoglobins

Identifiers

PMID35925991
PMCPMC9352045
OpenAlexW4289849143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.